«We must abandon the fiction that current oversight systems are adequate to protect volunteers in first-in-human trials or to steward scientific efforts»: this is the strong conclusion of a paper published in Nature by two [more]
As patents on the first generation of monoclonal antibodies begin to expire, the cancer community will need to get to grips with the unique issues involved in ensuring the safety and efficacy of copies of [more]
Could the new generation of antibodydrug conjugates herald a move away from conventional untargeted chemotherapy? Much will depend on how far and in whom their added benefit can justify the high cost of [more]
Dose too strongly and the patient gets more harm than benefit, too weakly and the drug cant do its job. Could oncology learn from other fields about using pharmacokinetics in the clinic to hit it [more]
Screening breast cancer patients for lymphoedema makes it possible to identify problems early and take action to halt its progression. Oncologists have an important role to play, particularly given the rise in lymphoedema rates that [more]